Three questions: 1.Was the correlation between antibody response and OS adjusted for baseline prognostic covariates? 2. Was antibody response measured during the same timeframe for all subjects and when?
3. Are the two antigens FLJ14668 and HLA-A24 specific to prostate cancer?
This is strong scientific validation for GVAX Phase 2 results.
This is wildly incorrect. To my knowledge **ALL** active immunotherapies show a strong correlation between some measure of immune responsiveness to vaccine and survival. Then the phase iii results come in a dud.
Seriously, find my an active immunotherapy that DIDN'T at some point tout exactly this kind of immune responsiveness. And all have failed to date.